US And Europe Hepatic Veno Occlusive Disease Treatment Market: By Drug Class, Antithrombin III Replacement, Defibrotide, Others), By Distribution Channel and Country
The hepatic venous-occlusive disease also known as Sinusoidal Obstruction Syndrome (SOS) is characterized by obstruction of small veins in the liver. In this condition, the blood gets blocked in the small veins, due to the blockage of blood in small veins, blood is congested in the liver which leads to a reduction of blood flow into the liver and damages the hepatic cells. Due to the congestion, the liver gets enlarged and finally causes liver cirrhosis. Hepatic veno-occlusive disease caused due to the long-term use of certain drugs, which can cause serious effects on the liver and during bone marrow and stem cell transplantation. There is no specific treatment for the veno-occlusive disease, however, it can be treated by normalizing the blood flow in hepatic blood vessels by controlling fibrin deposition and vasculitis. Europe's Hepatic Veno Occlusive Disease Treatment Market is in a nascent stage, as very few drugs are available for the treatment. Healthcare professionals are majorly focussing on alternative treatments to normalize the blood flow in hepatic small veins. Currently, market players are focusing on the development of new drugs for the treatment of hepatic veno-occlusive disease. Acquisitions and mergers, collaborations, and product launches are the key strategies followed by companies to increase their revenue share in the hepatic veno-occlusive treatment market. For instance, in July 2014, Jazz Pharmaceuticals, Plc. inked an agreement with Sigma-Tau Pharmaceuticals, Inc. to acquire rights to Defibrotide in the U.S. and all other countries of the Americas.
An increase in the prevalence of cancer diseases that require chemotherapy and radiotherapy, a rise in the adoption of bone marrow and stem cell transplantation, excessive consumption of alcohol, obesity, and a rise in the prevalence of viral hepatitis are anticipated to fuel the hepatic veno-occlusive disease market. Moreover, increases in R&D activities for the innovation of newer drugs, lifestyle changes, and increases in healthcare expenditure are boosting the hepatic-veno occlusive disease treatment market. However, lack of specific treatment options, a high cost of treatment, and stringent regulations and guidelines for drug approval might hinder the growth of the U.S. And Europe's Hepatic Veno Occlusive Disease Treatment Market.
Europe Hepatic Veno Occlusive Disease Treatment Market has been segmented into U.S. and Europe. U.S. accounted for the significant share in the market owing to increase in the prevalence of various oncology diseases, the sedentary lifestyle which leads to obesity and deposition of fat in blood vessels, and rise in R&D for the innovation of newer drugs. Europe hepatic veno occlusive disease treatment market exhibiting lucrative growth owing to the approval of defibrotide by European Commission, increase in the prevalence of genetic disorders, a rise in prevalence of liver cancer in Germany, Italy, and U.K., and increase in chemotherapy and radiotherapy procedures in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
By Drug Class |
|
|
By Distribution Channel |
|
Download Free Sample Report
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
